Market Overview

UPDATE: Morgan Stanley Reiterates on AbbVie After Competitor's Schizophrenia Drug Fails

AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
Liberal Interpretation Of IPO Helps This ETF Enjoy Facebook's Surge
Clinton's Price Caps Are A Non-Starter: Liana Moussatos Of Wedbush Securities (Seeking Alpha)

In a report published Tuesday, Morgan Stanley analyst David Risinger reiterated an Overweight rating on AbbVie (NYSE: ABBV), but removed the $57.00 price target.

In the report, Morgan Stanley noted, “Targacept's (not covered) cognitive deficits in schizophrenia (CDS) drug, TC-5619, failed. This drug is similar to ABBV's ABT-126, which is being tested in Ph. IIb in both cognition in Alzheimer's and CDS. We have been estimating 20% odds of ABBV success in one of the two indications.”

AbbVie closed on Monday at $53.37.

Latest Ratings for ABBV

Nov 2015Morgan StanleyUpgradesEqual-weightOverweight
Sep 2015CitigroupUpgradesNeutral
Jul 2015Deutsche BankMaintainsBuy

View More Analyst Ratings for ABBV
View the Latest Analyst Ratings

Posted-In: David Risinger Morgan StanleyAnalyst Color Price Target Analyst Ratings


Related Articles (ABBV)

Get Benzinga's Newsletters